175 related articles for article (PubMed ID: 32791085)
1. NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray.
Yang PS; Peng HY; Lin TB; Hsieh MC; Lai CY; Lee AS; Wang HH; Ho YC
Neuropharmacology; 2020 Nov; 178():108269. PubMed ID: 32791085
[TBL] [Abstract][Full Text] [Related]
2. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC
Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886
[TBL] [Abstract][Full Text] [Related]
3. Rapid antidepressant-like effects of muscarinic receptor antagonists require BDNF-dependent signaling in the ventrolateral periaqueductal gray.
Kan HW; Peng WH; Wu CC; Wang DW; Lee MT; Lee YK; Chu TH; Ho YC
Psychopharmacology (Berl); 2022 Dec; 239(12):3805-3818. PubMed ID: 36221037
[TBL] [Abstract][Full Text] [Related]
4. Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression.
Ho YC; Lin TB; Hsieh MC; Lai CY; Chou D; Chau YP; Chen GD; Peng HY
Neuropsychopharmacology; 2018 Jan; 43(2):302-312. PubMed ID: 28853438
[TBL] [Abstract][Full Text] [Related]
5. BDNF release and signaling are required for the antidepressant actions of GLYX-13.
Kato T; Fogaça MV; Deyama S; Li XY; Fukumoto K; Duman RS
Mol Psychiatry; 2018 Oct; 23(10):2007-2017. PubMed ID: 29203848
[TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
Chou D
Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
[TBL] [Abstract][Full Text] [Related]
7. Periaqueductal gray is required for controlling chronic stress-induced depression-like behavior.
Peng WH; Kan HW; Ho YC
Biochem Biophys Res Commun; 2022 Feb; 593():28-34. PubMed ID: 35051779
[TBL] [Abstract][Full Text] [Related]
8. Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.
Donello JE; Banerjee P; Li YX; Guo YX; Yoshitake T; Zhang XL; Miry O; Kehr J; Stanton PK; Gross AL; Burgdorf JS; Kroes RA; Moskal JR
Int J Neuropsychopharmacol; 2019 Mar; 22(3):247-259. PubMed ID: 30544218
[TBL] [Abstract][Full Text] [Related]
9. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.
Burgdorf J; Kroes RA; Zhang XL; Gross AL; Schmidt M; Weiss C; Disterhoft JF; Burch RM; Stanton PK; Moskal JR
Behav Brain Res; 2015 Nov; 294():177-85. PubMed ID: 26210936
[TBL] [Abstract][Full Text] [Related]
10. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Burgdorf J; Zhang XL; Nicholson KL; Balster RL; Leander JD; Stanton PK; Gross AL; Kroes RA; Moskal JR
Neuropsychopharmacology; 2013 Apr; 38(5):729-42. PubMed ID: 23303054
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13.
Lu Y; Wang C; Xue Z; Li C; Zhang J; Zhao X; Liu A; Wang Q; Zhou W
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25542689
[TBL] [Abstract][Full Text] [Related]
12. GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.
Liu RJ; Duman C; Kato T; Hare B; Lopresto D; Bang E; Burgdorf J; Moskal J; Taylor J; Aghajanian G; Duman RS
Neuropsychopharmacology; 2017 May; 42(6):1231-1242. PubMed ID: 27634355
[TBL] [Abstract][Full Text] [Related]
13. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
Burgdorf J; Zhang XL; Weiss C; Gross A; Boikess SR; Kroes RA; Khan MA; Burch RM; Rex CS; Disterhoft JF; Stanton PK; Moskal JR
Neuroscience; 2015 Nov; 308():202-11. PubMed ID: 26343295
[TBL] [Abstract][Full Text] [Related]
14. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
15. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Yang B; Zhang JC; Han M; Yao W; Yang C; Ren Q; Ma M; Chen QX; Hashimoto K
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3647-57. PubMed ID: 27488193
[TBL] [Abstract][Full Text] [Related]
16. BTRX-246040 Acts Through the Ventrolateral Periaqueductal Gray to Exert Antidepressant-Relevant Actions in Mice.
Li Z; Xu Y; Li R; Sheng Z; Chen X; Liu X; Lee CS; Peng HY; Lin TB; Hsieh MC; Lai CY; Wu HF; Chou D
Int J Neuropsychopharmacol; 2023 Jul; 26(7):483-495. PubMed ID: 37279653
[TBL] [Abstract][Full Text] [Related]
17. Decreased Glutamatergic Synaptic Strength in the Periaqueductal Gray Contributes to Maintenance of Visceral Pain in Male Rats with Experimental Pancreatitis.
Liu Q; Ko CY; Zheng C; Ye L; Liu B; Gao H; Huang D; Chou D
Neuroscience; 2020 Jan; 428():60-69. PubMed ID: 31887362
[TBL] [Abstract][Full Text] [Related]
18. The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
Moskal JR; Burgdorf JS; Stanton PK; Kroes RA; Disterhoft JF; Burch RM; Khan MA
Curr Neuropharmacol; 2017; 15(1):47-56. PubMed ID: 26997507
[TBL] [Abstract][Full Text] [Related]
19. Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
Ye L; Ko CY; Huang Y; Zheng C; Zheng Y; Chou D
Neuropharmacology; 2019 Oct; 157():107667. PubMed ID: 31207251
[TBL] [Abstract][Full Text] [Related]
20. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
Moskal JR; Burch R; Burgdorf JS; Kroes RA; Stanton PK; Disterhoft JF; Leander JD
Expert Opin Investig Drugs; 2014 Feb; 23(2):243-54. PubMed ID: 24251380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
